<DOC>
	<DOCNO>NCT00836901</DOCNO>
	<brief_summary>The objective study compare rate extent absorption amoxicillin-clavulanic acid 400 mg-57 mg chewable tablet ( test ) versus Augmentin® ( reference ) administer 1 x 400 mg-57 mg chewable tablet feed condition .</brief_summary>
	<brief_title>Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Inclusion Criteria Subjects females and/or male , nonsmoker , 18 year age old . Exclusion Criteria Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 ; heart rate le 50 bpm ) screening . Subjects BMI ≥30.0 . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject 's participation study . History allergic hypersensitivity reaction amoxicillin clavulanic acid relate drug ( e.g . penicillin , cephalosporin , cephamycins ) . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine , valproic acid ) use investigational drug participation investigation study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Any food allergy , intolerance , restriction special diet could , opinion Medical Subinvestigator , contraindicate subject 's participation study . Use prescription medication within 14 day prior administration study medication overthecounter product ) include natural product , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : less 300 mL whole blood within 30 day , 300 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day . Positive alcohol breath test screening . Subjects use tobacco form within 90 day precede study drug administration . Intolerance venipuncture . Subjects clinically significant history tuberculosis , epilepsy , asthma , diabetes , psychosis , glaucoma eligible study . Any history know Augmentinassociated cholestatic jaundice/hepatic dysfunction Any known active mononucleosis Subjects dentures brace . Additional exclusion criterion female subject : Breast feeding subject . Positive urine pregnancy test screening ( performed female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>